Some error occured while loading the Quick View. Please close the Quick View and try reloading the page.
More than 40 years after the official recognition of infantile autism in DSM-III, numerous questions remain about autism spectrum disorder (ASD)—its possible causes, assessment, and most effective treatments.
This second edition of the Textbook of Autism Spectrum Disorders features contributions from dozens of experts as it reviews the latest research on these topics and more.
As ambitious in
scope and exhaustive as the preceding edition, this guide is organized by
sections that tackle:
• Assessment and evaluation, including recognizing the lower- and
higher-order repetitive behaviors characteristic of ASD, as well as its
comorbidities. Chapters also discuss the roles that racial and ethnic
disparities, gender and sexual identities,and biomarkers and
technology—including smart home devices and augmented reality technology—can
play in assessment and evaluation.
• The possible causes of autism, from
prenatal, perinatal, and parental risk factors to syndromic causes of ASD,
updates on genetic testing, and the effect of environmental factors and
immune dysregulation.
• Standard and experimental treatments in autism.
Chapters analyze the role of pharmacotherapies such as serotonergic
antidepressants, atypical antipsychotics, and experimental therapeutics
(e.g., oxytocin, vasopressin) as well as the use of cannabis, cannabinoids,
and immunomodulatory agents. The book also examines behavioral treatments,
interventions in schools, complementary and integrative medicine approaches,
stem cell and gene therapies, and more.
• Social policy issues,
including the role of patient advocacy groups in treatment development and
an examination of autism strengths and the growing emphasis on recognizing
neurodiversity.
Unrivaled in its thoroughness, the book includes summary points in each chapter for ease of reference and lists of recommended readings that offer readers the opportunity for further study and exploration. For all those in the ASD continuum of care—psychiatrists, psychologists, neurologists, social workers, speech therapists, educators, and patient families—this is an essential resource.
The text goes beyond a just-the-facts listing of research
findings to consider public health and ethical considerations of assessment,
treatment, and even conceptualization of ASD. The depth of coverage provided
to comorbidities and syndromic causes and the emerging role of the research
being led by individuals with ASD was excellent. The authors address each
major chapter with statements supported by ample current research, presented
in a detail-rich but digestible overview of design and findings. This
textbook is unlike any other I have seen, and makes fascinating reading for
the ASD professional, regardless of years of experience.
In summary,
the strengths of this textbook include its breadth and depth of coverage,
and the massive number of research studies presented to support the body of
the chapters.
This text is very comprehensive, yet written in a
reader-friendly format that would support most professionals or
preprofessional students. I would recommend it for all
practitioners-in-training or practices that support individuals with
ASD.
— Teresa Daly. PhD
Eric Hollander, M.D., is the Director of the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York.
Randi Hagerman, M.D., is the Endowed Chair in Fragile X Research for the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Distinguished Professor of Pediatrics in the Department of Pediatrics at the University of California, Davis Medical Center in Sacramento, California.
Casara Ferretti, M.S., M.A., is a Predoctoral Research Associate in the Autism and Obsessive Compulsive Spectrum Program at the Psychiatric Research Institute of Montefiore Einstein and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine, in Bronx, New York. She is a PhD candidate in the Clinical Psychology PhD program with Health Emphasis at Ferkauf Graduate School of Psychology, Yeshiva University.
Foreword
PART I: Assessment, Evaluation, and Target
Symptoms
PART IA: Assessment and Evaluation
Chapter
1. Epidemiology
Chapter 2. Psychiatric Assessment and
Treatment
Chapter 3. Pediatric and Neurological Assessments
Chapter
4. Gender Dysphoria, Gender Incongruence, and Sexual Identity
Chapter 5.
Racial and Ethnic Disparities in Assessment and Evaluation
Chapter 6.
Digital Biomarkers in Diagnostics and Monitoring
PART IB: Target and
Comorbid Symptoms
Chapter 7. Social Communication
Chapter 8.
Diet and Nutrition
PART II: Causes
PART IIA:
Overview
Chapter 9. Genetics and Genomics
Chapter 10.
Epigenomics
Chapter 11. Prenatal, Perinatal, and Parental Risk
Factors
Chapter 12. Animal Models
Chapter 13. Electrophysiological
Studies
Chapter 14. Environmental Toxicity and Immune
Dysregulation
PART IIB: Syndromic Causes
Chapter 15.
Overview of Syndromic Causes of Autism and Commonalities in Neurobiological
Pathways
Chapter 16. Fragile X Syndrome and Associated
Disorders
Chapter 17. Tuberous Sclerosis Complex
Chapter 18. 16p11.2
and Other Recurrent Copy Number Variants Associated With ASD
Susceptibility
Chapter 19. Rett Syndrome
Chapter 20. Prader-Willi
Syndrome
PART IIC: Imaging and Anatomy
Chapter 21.
Neuroanatomical Findings
Chapter 22. The Amygdala in ASD
Chapter 23.
Neurobiology of ASD Informed by Structural Imaging Research
Chapter 24.
Positron Emission Tomography
Chapter 25. Functional Magnetic Resonance
Imaging
PART III: Treatments and Interventions
PART
IIIA: Standard Pharmacological Treatments
Chapter 26.
Serotonergic Medication
Chapter 27. Antipsychotics
Chapter 28.
Treating Hyperactivity in Children With Pervasive Developmental
Disorders
PART IIIB: Experimental Therapeutics
Chapter
29. Complementary and Integrative Approaches
Chapter 30.
Oxytocin
Chapter 31. Vasopressin
Chapter 32.
N-Acetylcysteine
Chapter 33. Arbaclofen: From Animal Models to Clinical
Trials
Chapter 34. Cannabis, Cannabinoids, and Immunomodulatory
Agents
PART IIIC: Behavioral and Educational
Interventions
Chapter 35. Behavioral Treatments
Chapter 36.
Early Start Denver Model
Chapter 37. The Developmental, Individual
Difference, Relationship-Based Intervention Model: A Comprehensive
Parent-Mediated Approach
Chapter 38. School-Based
Interventions
Chapter 39. Language and Communication: Challenges and
Treatments
PART IIID: Future Treatment
Developments
Chapter 40. Transcranial Magnetic
Stimulation
Chapter 41. Stem Cell and Gene Therapy
Chapter 42. Gene
Therapy and Molecular Interventions
PART IV: Consortiums, Employment,
and Advocacy
Chapter 44. Consortiums:
Developing Precision
Medicine Approaches to ASD Conditions
Autism Biomarkers Consortium for
Clinical Trials
Interactive Autism Network
Chapter 45. Autism
Strengths and Neurodiversity
Chapter 46. Role of Patient Advocacy Groups
in Treatment Development
Index